Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
SANGAMO THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2025 EARNINGS CALL
-
Sangamo has now submitted the ST-920 preclinical and clinical modules to the FDA for review.
-
SANGAMO THERAPEUTICS PRESENTS DETAILED DATA FROM REGISTRATIONAL STAAR STUDY IN FABRY DISEASE AT WORLDSYMPOSIUM 2026
-
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
-
Sangamo announces it has begun a rolling submission of its BLA to the FDA for , an investigational gene therapy for adults with Fabry disease
-
Sangamo Therapeutics today announced that the FDA has granted Fast Track Designation to ST-503 in chronic neuropathic pain
-
U.S. FDA has accepted Sangamo’s request for a rolling submission and review of the BLA for ST-920 in Fabry disease
-
SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND THIRD QUARTER 2025 FINANCIAL RESULTS
-
SANGAMO THERAPEUTICS ANNOUNCES THIRD QUARTER 2025 EARNINGS CALL
-
SANGAMO THERAPEUTICS PRESENTS DETAILED DATA FROM REGISTRATIONAL STAAR STUDY IN FABRY DISEASE AT INTERNATIONAL CONGRESS OF INBORN ERRORS OF METABOLISM 2025